How Audi Is Trying To Claw Its Way Back From A 30% U.S. Sales Drop
Audi is struggling with a 30% U.S. sales drop and three consecutive years of double-digit losses, facing headwinds from tariffs, plummeting EV sales, and lack of domestic manufacturing. The company is launching new SUVs, including the Q9 three-row model, to compete in the premium segment where SUVs represent over 80% of sales, but tariff-driven price increases threaten its historical value-for-money positioning.
Summary
Audi is experiencing significant challenges in the U.S. market, posting a 30% sales drop in the first quarter and tracking toward its third consecutive year of double-digit losses despite an otherwise stable market. The German luxury brand has fallen from its historically strong position as a formidable competitor to BMW and Mercedes-Benz, having lost ground since 2020. Quality issues compound the problem, with Audi ranking last in J.D. Power initial quality surveys. The company has attributed its decline primarily to steep tariffs and the end of federal EV subsidies, which have forced price increases precisely when Audi's competitive advantage relied on offering good value for money as the lower-priced German luxury alternative.
To counter these challenges, Audi unveiled three new vehicles including the Q9 three-row SUV and its high-performance SQ9 variant, featuring advanced technology like smart headlights and OLED lighting previously unavailable in the U.S. market. Audi claims this lineup represents the youngest premium SUV offerings in America, targeting the 80%+ of the premium market dominated by SUVs. However, Audi faces structural disadvantages compared to rivals: while Mercedes-Benz and BMW operate U.S. factories, Audi has none and relies entirely on imports, making it more vulnerable to tariff impacts. The company is considering moving some production to Volkswagen Group's Scout factory in South Carolina, scheduled to open in 2027.
Expectations for the Q9 are measured—analysts project 20,000 to 30,000 annual U.S. sales, a fraction of Audi's 2025 total of 165,000 vehicles (itself a 16% decline from 2024). While the three-row segment is crowded with competition from both German and American automakers, analysts suggest the Q9 could still contribute meaningfully to company profits through higher margins per vehicle rather than volume. The broader challenge remains tariffs and market dynamics, which are expected to continue dominating Audi's U.S. performance regardless of new product launches.
Key Insights
- Audi has been last in J.D. Power initial quality surveys, with the brand's struggles stemming from quality issues that emerged since 2020, compounding its sales decline in an otherwise stable market.
- Tariff-driven price increases are especially damaging to Audi because the brand's core competitive advantage for decades was value-for-money positioning as the lower-priced German luxury alternative to BMW and Mercedes-Benz.
- Unlike rivals Mercedes-Benz and BMW which operate U.S. factories, Audi has no domestic manufacturing and imports all vehicles it sells in America, making it disproportionately vulnerable to tariff impacts.
- Audi invested substantially in EV production expecting significant returns, but the gap between expectations and market realities proved particularly substantial for the brand compared to other manufacturers.
- Analysts project the Q9 will sell only 20,000 to 30,000 units annually in America—a fraction of Audi's 165,000 vehicles sold in 2025—but it could still substantially contribute to the bottom line if sold at high profit margins per vehicle.
Topics
Transcript
[0:00] Faced with steep tariffs, plummeting EV sales and an unstable, unpredictable global market, German luxury brand Audi is trying to claw its way back from a 30% drop in sales in the first quarter of the year. Audi has really been struggling in the US. They're on track for the third consecutive year of double digit sales losses. And I mean, that's hard to do in a market that has been up, if not level. The brand just unveiled the latest in an onslaught of products aimed right at the heart of the US market, the Q9 three row SUV. [0:32] We went to see it. This is the Audi Q9. We also saw the high performance SQ9 which…
Full transcript available for MurmurCast members
Sign Up to AccessMore from CNBC
What Do Banks Risk Working With Trump’s $858 Million Investment Portfolio?
CNBC investigation reveals that JPMorgan Chase, Charles Schwab, UBS, and Stephens Incorporated manage at least four of President Trump's eight investment accounts, which collectively held $858 million in 2025 and generated over 21,000 trades. Financial institutions face significant compliance and reputational risks from managing a sitting president's wealth, while gaining valuable access to presidential influence as compensation.
Why Fed Chairman Warsh Says 'Inflation Is A Choice'
Fed Chairman Kevin Warsh argues that inflation is fundamentally a choice and responsibility of the Federal Reserve, not an inevitable economic force. The transcript explores how this perspective shapes Fed policy communication and decision-making, while acknowledging the complexity of distinguishing between supply shocks and demand-driven inflation.
How Retail Investors Are Using AI To Make Trades
The transcript explores the evolution of AI in retail investing, moving from AI-powered research tools to autonomous agents that can execute trades on behalf of investors. While some retail investors are building custom AI agents using tools like Claude, current implementations maintain human oversight through approval workflows, with companies cautiously implementing guardrails before AI can act independently on real money.
Why Europe is betting big on drones
Europe is dramatically increasing investment in military drone technology and AI-powered autonomous systems, driven by lessons learned from the Ukraine war. Recent developments include NATO's drone initiative, UK funding pledges, German orders for Ukraine, and major defense tech valuations, signaling that drones and their supporting technologies are now central to modern military strategy.
This new Medicare program offers obesity drugs for $50 a month. Here's what you need to know
Medicare has launched a new pilot program called Bridge that allows eligible seniors to access GLP-1 obesity drugs from Novo Nordisk and Eli Lilly for $50 per month copays, starting this week. This represents a major policy shift as Medicare has historically excluded obesity medications from coverage, and could potentially reach millions of beneficiaries and expand access to drugs that normally cost hundreds of dollars monthly.